Changes in plasma vascular endothelial growth factor at 8 weeks after sorafenib administration as predictors of survival for advanced hepatocellular carcinoma
出版年份 2013 全文链接
标题
Changes in plasma vascular endothelial growth factor at 8 weeks after sorafenib administration as predictors of survival for advanced hepatocellular carcinoma
作者
关键词
-
出版物
CANCER
Volume 120, Issue 2, Pages 229-237
出版商
Wiley
发表日期
2013-10-12
DOI
10.1002/cncr.28384
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma
- (2015) et al. JOURNAL OF HEPATOLOGY
- Efficacy, Safety, Pharmacokinetics, and Biomarkers of Cediranib Monotherapy in Advanced Hepatocellular Carcinoma: A Phase II Study
- (2013) A. X. Zhu et al. CLINICAL CANCER RESEARCH
- Plasma Biomarkers as Predictors of Outcome in Patients with Advanced Hepatocellular Carcinoma
- (2012) J. M. Llovet et al. CLINICAL CANCER RESEARCH
- Relationship between baseline hepatic status and outcome, and effect of sorafenib on liver function: SHARP trial subanalyses
- (2012) Jean-Luc Raoul et al. JOURNAL OF HEPATOLOGY
- Usefulness of alpha-fetoprotein response in patients treated with sorafenib for advanced hepatocellular carcinoma
- (2012) Nicola Personeni et al. JOURNAL OF HEPATOLOGY
- Comparison of tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma
- (2011) Julien Edeline et al. CANCER
- Management of Hepatocellular Carcinoma in Japan: Consensus-Based Clinical Practice Guidelines Proposed by the Japan Society of Hepatology (JSH) 2010 Updated Version
- (2011) Masatoshi Kudo et al. DIGESTIVE DISEASES
- Management of hepatocellular carcinoma: An update
- (2011) Jordi Bruix et al. HEPATOLOGY
- Early Decrease in α-Fetoprotein, but Not Des-γ-Carboxy Prothrombin, Predicts Sorafenib Efficacy in Patients with Advanced Hepatocellular Carcinoma
- (2011) Teiji Kuzuya et al. ONCOLOGY
- Early alpha-fetoprotein response predicts treatment efficacy of antiangiogenic systemic therapy in patients with advanced hepatocellular carcinoma
- (2010) Yu-Yun Shao et al. CANCER
- V-CLIP: Integrating plasma vascular endothelial growth factor into a new scoring system to stratify patients with advanced hepatocellular carcinoma for clinical trials
- (2010) Ahmed O. Kaseb et al. CANCER
- Effect of sorafenib on murine liver regeneration
- (2010) Caroline Hora et al. HEPATOLOGY
- Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma
- (2010) Riccardo Lencioni et al. SEMINARS IN LIVER DISEASE
- Prognostic role of vascular endothelial growth factor in hepatocellular carcinoma: systematic review and meta-analysis
- (2009) S J Schoenleber et al. BRITISH JOURNAL OF CANCER
- Vascular endothelial growth factor in the management of hepatocellular carcinoma
- (2009) Ahmed O. Kaseb et al. CANCER
- Phase II Trial Evaluating the Clinical and Biologic Effects of Bevacizumab in Unresectable Hepatocellular Carcinoma
- (2008) Abby B. Siegel et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
- (2008) Ann-Lii Cheng et al. LANCET ONCOLOGY
- Sorafenib in Advanced Hepatocellular Carcinoma
- (2008) Josep M. Llovet et al. NEW ENGLAND JOURNAL OF MEDICINE
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started